JP2005320298A - 癌治療のための薬剤 - Google Patents

癌治療のための薬剤 Download PDF

Info

Publication number
JP2005320298A
JP2005320298A JP2004140976A JP2004140976A JP2005320298A JP 2005320298 A JP2005320298 A JP 2005320298A JP 2004140976 A JP2004140976 A JP 2004140976A JP 2004140976 A JP2004140976 A JP 2004140976A JP 2005320298 A JP2005320298 A JP 2005320298A
Authority
JP
Japan
Prior art keywords
antibody
drug
cancer
cells
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004140976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005320298A5 (https=
Inventor
Kiyohiko Hatake
清彦 畠
Yasuhito Terui
康仁 照井
Takuma Sakurai
琢磨 桜井
Yuji Mishima
雄二 三嶋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Priority to JP2004140976A priority Critical patent/JP2005320298A/ja
Publication of JP2005320298A publication Critical patent/JP2005320298A/ja
Publication of JP2005320298A5 publication Critical patent/JP2005320298A5/ja
Pending legal-status Critical Current

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004140976A 2004-05-11 2004-05-11 癌治療のための薬剤 Pending JP2005320298A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004140976A JP2005320298A (ja) 2004-05-11 2004-05-11 癌治療のための薬剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004140976A JP2005320298A (ja) 2004-05-11 2004-05-11 癌治療のための薬剤

Publications (2)

Publication Number Publication Date
JP2005320298A true JP2005320298A (ja) 2005-11-17
JP2005320298A5 JP2005320298A5 (https=) 2006-04-13

Family

ID=35467820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004140976A Pending JP2005320298A (ja) 2004-05-11 2004-05-11 癌治療のための薬剤

Country Status (1)

Country Link
JP (1) JP2005320298A (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010281656A (ja) * 2009-06-04 2010-12-16 Kanazawa Univ 白血病治療剤及び該治療剤の新規なスクリーニング方法
JP2019525138A (ja) * 2016-06-16 2019-09-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009064979, Ｍｏｌｅｃｕｌａｒ Ｉｍｍｕｎｏｌｏｇｙ, 2003, Ｖｏｌ．４０、ｐ．１０９−１２３, ｐ．１１５−１１７ *
JPN6009064982, Ｎａｔｕｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ, 2003, Ｖｏｌ．２１、Ｎｏ．１２, ｐ．１４５９、ｐ．１４６１−１４６３ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010281656A (ja) * 2009-06-04 2010-12-16 Kanazawa Univ 白血病治療剤及び該治療剤の新規なスクリーニング方法
JP2019525138A (ja) * 2016-06-16 2019-09-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法

Similar Documents

Publication Publication Date Title
EP2513146B1 (en) Antibodies against ror1 capable of inducing cell death of cll
Chatterjee et al. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells
Lin et al. Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression
JP4467559B2 (ja) 細胞増殖を阻害する組成物および方法
Wang et al. CD4+ T helper 2 cell–macrophage crosstalk induces IL-24–mediated breast cancer suppression
EP2038414A2 (en) Cancer therapy using bcl-xl-specific sina
KR20130102990A (ko) 항암면역우회암의 표시인자 및 무력화 표적으로서의 ａｐｉ５의 용도
JP2007530431A (ja) 膵臓癌を治療するための組成物および方法
EP2742950B1 (en) Pharmaceutical composition containing fibulin-3 protein as an active ingredient for inhibiting the growth of cancer stem cells
KR102670312B1 (ko) Wdr34 억제제를 포함하는 암줄기세포 성장 억제용 조성물 및 그 용도
JP5176035B2 (ja) Ｄｒｅｆを分子標的とする癌治療用組成物
JP2005320298A (ja) 癌治療のための薬剤
JP2005320298A5 (https=)
JP6176800B2 (ja) Ｌｉｘ１ｌ高発現腫瘍細胞の増殖阻害方法、及び腫瘍細胞増殖抑制ペプチド
US8343940B2 (en) Method for enhancing chemical sensitivity or radiosensitivity of cancer cells by inhibiting expression of TSPYL5
WO2013025936A1 (en) Detection and treatment of metastatic disease
EP4039273A1 (en) Monoclonal antibody or antibody fragment against canine cd20
JP6653130B2 (ja) 抗がん剤
US20250228895A1 (en) Compounds to inhibit ythdf2, t helper cells lacking expression of ythdf2, and methods to treat cancer
CN118546926A (zh) 寡核苷酸分子及其在肿瘤治疗中的应用
AU2009279375B2 (en) Methods of treating and preventing glucose toxicity
JPWO2006016574A1 (ja) ＲＮＡｉを利用した抗腫瘍剤
Farina CDK5 Involvement in Cancer and in the Tumor Microenvironment
EP4682255A1 (en) Composition and use thereof
Chung The Regulatory Role and Mechanism of Smad3 in Tumor-associated Neutrophils in Lung Carcinoma

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100511